FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594851455> ?p ?o ?g. }

• W2594851455 abstract "Abstract Introduction Patients with residual disease following initial treatment of chronic lymphocyticleukemia(CLL) withfludarabine, cyclophosphamide and rituximab (FCR) chemotherapy have reduced progression free (PFS) and overall survival (OS). The CLL6 RESIDUUM trial is a joint trial of the Australasian Leukaemia and Lymphoma Group (ALLG) and the French CLL branch of the French InnovativeLeukemiaOrganization (FILO) thatanalyzesthe role oflenalidomide(LEN) as consolidation therapy in patients following front-line treatment for CLL who do not enter minimal residual disease (MRD) negative complete remission. Methods CLL patients with CIRS score <6 requiring treatment according to iwCLLcriteria receive 6 cycles of FCR. Following completion of treatment, those with clinical, radiological and/or multiparameterflow cytometry (MFC) evidence of residual CLL in blood or bone marrow are randomized 1:1 to receive 2 years of maintenance treatment with LEN 10 mg daily or observation (OBS). Patients are reviewed for evidence of clinical progression, and peripheral blood and bone marrow are sampled regularly for evidence of MRD. CT scans are performed until resolution of lymphadenopathy and splenomegaly. Flow analysis for MRD is performed at two central laboratories using ERIC accredited methodology to achieve a sensitivity of 10-4. The primary end point of the study is time to progression or death. Results As of end of July 2016, data from 79 patients randomized on the study were analyzedfor the effects of consolidation treatment on blood and marrow MRD. Median duration from randomization was 488 days. There were 63 males and 16 females. Median age was 62 years (range 29 to 81). 37 patients were randomized to receive LEN, 42 to OBS .On the LEN arm 13, 3 and 21 patientsvs 12, 9 and 21 on the OBS arm were in CR, nodular PR and PR respectively at the time of randomization. There were 26 serious adverse events (SAEs) reported in 22 patients. 12 SAEs in 11 patients were attributed to LEN including pneumonia/chest infection (n=4), pulmonary infiltrate (1), prostatitis (1) second primary malignancy (SPM) (1), vomiting (1), neutropenia (1), tumorflare (1), acute kidney injury (1) and anal warts (1). There were 5 SAEs in the OBS arm comprising SPM (2), neutropenia (1), gout (1) and GuillainBarre syndrome(1). Peripheral blood samples were analyzedprior to consolidation and at 3, 6 and 12 months and every 6 months thereafter. MRD levels during consolidation were compared with pre-consolidation levels and categorized as increasing, decreasing, stable detectable or stable undetectable (Fig 1). MRD increased over the period of observation in 38% of patient on the LEN arm and in 62% of patients on the OBS arm (p = 0.032, Χ2). 10 patients (27%) in the LEN arm and 2 patients (5%) in the control arm had decreasing levels of MRD in the blood (p = 0.006, Χ2). There was no difference between consolidation treatments in the percentage of patients with stable blood MRD measurements, whether in the detectable or the undetectable range. The effect of LEN was most apparent in patients in PR at randomization where 5 patients (24%) taking LEN had increasing MRD in the blood compared to 15 patients (71%) on the OBS arm (p = 0.002, Χ2). Bone marrow MRD levels were assessed prior to consolidation and after 12 months in 9 patients in each arm of the study (LEN arm 2 CR, 1 nPR, 6 PR; OBS arm 4 CR, 1 nPR, 4 PR at randomization). Eight patients in the LEN arm and 2 patients in the OBS arm were observed to have a reduction in marrow MRD. There was a significant reduction between the 2 time points in the LEN arm (p=0.022 paired Wilcoxon test) but not in the OBS arm. Four of 9 patients in the LEN arm and 1 patient in the OBS arm achieved marrow MRD values below 10-4 after 1 year on trial. Conclusion LEN consolidation therapy for residual disease after FCR front-line therapy for CLL is associated with improved control of MRD in both blood and bone marrow. A large group of recently randomized patients will provide more data to determine whether these encouraging results will translate into improved progression free and overall survival. Figure 1 Percentage of patients on LEN and OBS arms with increasing, decreasing, stable detectable or stable undetectable MRD. Figure 1. Percentage of patients on LEN and OBS arms with increasing, decreasing, stable detectable or stable undetectable MRD. Disclosures Gottlieb: Indee: Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees. Aurran:Janssen: Honoraria. Tam:Gilead: Honoraria; Roche: Honoraria; Abbvie: Honoraria; Janssen: Honoraria. Letestu:Roche: Honoraria; Alexion: Honoraria. Levy:Roche: Honoraria; Gilead: Honoraria; Abbive: Honoraria; Janssen: Honoraria. Leblond:Roche: Honoraria; Gilead: Honoraria; Janssen: Honoraria; Abbvie: Honoraria. Mulligan:GSK: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau. Cymbalista:Abbvie: Honoraria; Roche: Honoraria; Janssen: Consultancy, Research Funding; Gilead: Consultancy, Honoraria." @default.
• W2594851455 created "2017-03-16" @default.
• W2594851455 creator A5001949103 @default.
• W2594851455 creator A5004617126 @default.
• W2594851455 creator A5007604802 @default.
• W2594851455 creator A5015131529 @default.
• W2594851455 creator A5028727344 @default.
• W2594851455 creator A5034517642 @default.
• W2594851455 creator A5057098654 @default.
• W2594851455 creator A5063041359 @default.
• W2594851455 creator A5067831062 @default.
• W2594851455 creator A5068303471 @default.
• W2594851455 creator A5075546030 @default.
• W2594851455 creator A5085780727 @default.
• W2594851455 creator A5087985272 @default.
• W2594851455 date "2016-12-02" @default.
• W2594851455 modified "2023-09-30" @default.
• W2594851455 title "Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)" @default.
• W2594851455 doi "https://doi.org/10.1182/blood.v128.22.2053.2053" @default.
• W2594851455 hasPublicationYear "2016" @default.
• W2594851455 type Work @default.
• W2594851455 sameAs 2594851455 @default.
• W2594851455 citedByCount "3" @default.
• W2594851455 countsByYear W25948514552017 @default.
• W2594851455 countsByYear W25948514552018 @default.
• W2594851455 countsByYear W25948514552022 @default.
• W2594851455 crossrefType "journal-article" @default.
• W2594851455 hasAuthorship W2594851455A5001949103 @default.
• W2594851455 hasAuthorship W2594851455A5004617126 @default.
• W2594851455 hasAuthorship W2594851455A5007604802 @default.
• W2594851455 hasAuthorship W2594851455A5015131529 @default.
• W2594851455 hasAuthorship W2594851455A5028727344 @default.
• W2594851455 hasAuthorship W2594851455A5034517642 @default.
• W2594851455 hasAuthorship W2594851455A5057098654 @default.
• W2594851455 hasAuthorship W2594851455A5063041359 @default.
• W2594851455 hasAuthorship W2594851455A5067831062 @default.
• W2594851455 hasAuthorship W2594851455A5068303471 @default.
• W2594851455 hasAuthorship W2594851455A5075546030 @default.
• W2594851455 hasAuthorship W2594851455A5085780727 @default.
• W2594851455 hasAuthorship W2594851455A5087985272 @default.
• W2594851455 hasConcept C126322002 @default.
• W2594851455 hasConcept C141071460 @default.
• W2594851455 hasConcept C2776694085 @default.
• W2594851455 hasConcept C2776755627 @default.
• W2594851455 hasConcept C2777063308 @default.
• W2594851455 hasConcept C2777938653 @default.
• W2594851455 hasConcept C2778461978 @default.
• W2594851455 hasConcept C2779263901 @default.
• W2594851455 hasConcept C2779338263 @default.
• W2594851455 hasConcept C2780653079 @default.
• W2594851455 hasConcept C71924100 @default.
• W2594851455 hasConcept C90924648 @default.
• W2594851455 hasConceptScore W2594851455C126322002 @default.
• W2594851455 hasConceptScore W2594851455C141071460 @default.
• W2594851455 hasConceptScore W2594851455C2776694085 @default.
• W2594851455 hasConceptScore W2594851455C2776755627 @default.
• W2594851455 hasConceptScore W2594851455C2777063308 @default.
• W2594851455 hasConceptScore W2594851455C2777938653 @default.
• W2594851455 hasConceptScore W2594851455C2778461978 @default.
• W2594851455 hasConceptScore W2594851455C2779263901 @default.
• W2594851455 hasConceptScore W2594851455C2779338263 @default.
• W2594851455 hasConceptScore W2594851455C2780653079 @default.
• W2594851455 hasConceptScore W2594851455C71924100 @default.
• W2594851455 hasConceptScore W2594851455C90924648 @default.
• W2594851455 hasLocation W25948514551 @default.
• W2594851455 hasOpenAccess W2594851455 @default.
• W2594851455 hasPrimaryLocation W25948514551 @default.
• W2594851455 hasRelatedWork W2519601971 @default.
• W2594851455 hasRelatedWork W2531770526 @default.
• W2594851455 hasRelatedWork W2547353143 @default.
• W2594851455 hasRelatedWork W2591645154 @default.
• W2594851455 hasRelatedWork W2594854362 @default.
• W2594851455 hasRelatedWork W2595988118 @default.
• W2594851455 hasRelatedWork W2596050981 @default.
• W2594851455 hasRelatedWork W2597924550 @default.
• W2594851455 hasRelatedWork W2735715421 @default.
• W2594851455 hasRelatedWork W2912434766 @default.
• W2594851455 hasRelatedWork W2913479341 @default.
• W2594851455 hasRelatedWork W2954522556 @default.
• W2594851455 hasRelatedWork W2979710073 @default.
• W2594851455 hasRelatedWork W2979958839 @default.
• W2594851455 hasRelatedWork W2983698703 @default.
• W2594851455 hasRelatedWork W2989071867 @default.
• W2594851455 hasRelatedWork W3015486851 @default.
• W2594851455 hasRelatedWork W3183608863 @default.
• W2594851455 hasRelatedWork W3193140429 @default.
• W2594851455 hasRelatedWork W560288462 @default.
• W2594851455 isParatext "false" @default.
• W2594851455 isRetracted "false" @default.
• W2594851455 magId "2594851455" @default.
• W2594851455 workType "article" @default.